IL-6: To immunity and beyond

Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, Jones, Simon ORCID: https://orcid.org/0000-0001-7297-9711, Aletaha, Daniel, Takeuchi, Tsutomu, McInnes, Iain and Smolen, Josef S 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2 (1) , pp. 19-23. 10.1136/conmed-2018-000004

Full text not available from this repository.

Abstract

Interleukin (IL)−6 inhibition has been approved for the treatment of rheumatoid arthritis, systemic juvenile arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and, in some countries, Castleman’s disease. IL-6 has also been implicated in several non-rheumatoid arthritis inflammatory and immune conditions such as systemic sclerosis, vasculitides, systemic lupus erythematous, and psoriatic arthritis. In orphan diseases, such as systemic sclerosis, which are associated with significant morbidity and mortality and for which there are no approved treatments, IL-6 inhibition may offer a promising treatment strategy. It is also becoming clear that IL-6 may have an important role not only in inflammatory and immune diseases but also in nonimmune mediated diseases such as endogenous depression and depression associated with chronic inflammatory conditions. Several studies have explored the effect of IL-6 pathway inhibition in Crohn’s disease and adult-onset Still’s disease, suggesting that IL-6 may be important in their pathogenesis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
ISSN:	2515-3927
Related URLs:	https://considerations.bmj.com/content/2...
Date of Acceptance:	31 May 2018
Last Modified:	26 Nov 2022 13:22
URI:	https://orca.cardiff.ac.uk/id/eprint/131161

Actions (repository staff only)

Edit Item